Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Regeneron's COVID drug sales outside U.S. help revenue beat

Economy May 04, 2022 04:06PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. A vial of Regeneron monoclonal antibody sits on a medical table as registered nurse Jessica Krumwiede attempts to find a vein to administer it to Cathy Hardin, who was vaccinated prior to testing positive for the coronavirus disease (COVID-19), at the Sar

(Reuters) - Regeneron (NASDAQ:REGN) Pharmaceuticals reported better-than-expected revenue aided by sales from its COVID-19 antibody outside the United States and strong demand for its blockbuster drugs Dupixent and Eylea.

About $216 million in first-quarter sales from the intravenous COVID drug through a partnership with Roche, which sells the drug outside the United States under brand name Ronapreve, helped Regeneron limit the setback from no sales in the United States - its biggest market.

Regeneron in February warned it will record zero sales from the intravenous COVID drug in the United States for the first quarter after the U.S. Food and Drug Administration limited its use due to lack of effectiveness against the Omicron coronavirus variant.

The drugmaker is now working on experimental "next generation" antibodies that are tailored against variants including those of Omicron-lineage.

It was the revenue from Roche collaboration that helped in the topline beat, Wells Fargo (NYSE:WFC) analyst Mohit Bansal said in a note.

Shares of Regeneron were marginally up at $668 in premarket trade, after the company said its overall sales grew 17% to $2.97 billion in the first quarter, which was higher than the average analyst estimate of $2.72 billion, as per Refinitiv IBES data.

Eczema treatment Dupixent and macular degeneration drug Eylea recorded sales growth of 11% and 43%, respectively.

They have been key drivers for the company's earnings growth, and the company and analysts are both optimistic about further growth for the two drugs.

Regeneron's French partner Sanofi (NASDAQ:SNY) SA, which records the sales from Dupixent, raised its peak sales target for Dupixent to more than 13 billion euros ($14.3 billion) in late March.

Regeneron's net profit in the quarter ended March 31 fell 13% to $974 million from a year earlier.

(This story corrects to say "intravenous COVID drug", not "COVID pill", in paragraph 2 and 3. The error was repeated in a previous version of the story)

Regeneron's COVID drug sales outside U.S. help revenue beat
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email